View Article

Abstract

Environmental monitoring is a study Programme designed to study load of Viable Microorganism as well as Non-Viable Particles present in (controlled and classified area) environment. The use of risk assessment approaches is an important current Good Manufacturing Practice (cGMP) tool in microbiological environmental monitoring Programme. The study was designed to conduct Risk assessment study for fixing sampling point and location for conducting environmental Monitoring in Classified area. Clean rooms were divided into five groups based on different Production activities done in the plant and further the individual rooms were divided in to five different sample spot based on risk of contamination of products during activities to find the Hot spot areas for higher microbial load. Finger dab test was performed to detect the hygiene and sanitization practices in plant. In-house limit of 100 cfu was set for finger dab test as non-sterile formulation was done in plant and result was found satisfactory. The data of non-viable count was taken from third party report performed annualy during rest condition. 0.5 micron and 5.0-micron particle was tested in class D area and result was satisfactory. The obtained data suggests that the worst case location is “Near Return Air Loop” in the classified areas. This location can be selected as “Hot Spot” for regular environmental monitoring of rooms..

Keywords

Environment Monitoring Test, TAMC, TYMC, Classified Area, Finger Dab Test.

Introduction

Environmental monitoring is a study Programme designed to study load of Viable Microorganism as well as Non-Viable Particles present in (controlled and classified area) environment. The use of risk assessment approaches is an important current Good Manufacturing Practice (cGMP) tool in microbiological environmental monitoring Programme (1). The prime goal of environmental monitoring of cleanrooms are to regulate the numbers of airborne viable and non-viable particles within defined limits, predict the risk to the environment and regularly estimate the efficacy of cleaning and disinfecting processes (2). Pharmaceutical manufacturing comprises a complicated, multi-phase processing system associated with major risks of microbial contamination through diverse sources. The product quality is greatly influenced by microbial contamination in several processing steps. There are two types of pharmaceutical products currently being manufactured are sterile and non-sterile products (3) Environment plays key role in microbial access in Pharmaceutical and biological products. The quality of product depends on environmental controls in manufacturing area. To obtain a pharmaceutical product free of contamination, you need an adequate environmental monitoring system. The system includes identification, testing and removal of bioburden to ensure the quality of product (4). The frequency of monitoring ensures contamination free environment maintenance. Environmental monitoring is a programed scheme to explain the regulation of viable and non-viable particles in critical sites (5).

Clean Rooms

Clean Area Separation is a segregation area which is required between classified area and external environment to prevent cross contamination. According to WHO classification, it as classified as Class A, Class B,Class C and Class D and according to ISO Classification ,it is classified as ISO 5,ISO 6, ISO 7 and ISO 8 (6).

Risk Assessment approach

These risk assessment approaches are not only concerned with selecting environmental monitoring locations. They integrate the environmental monitoring system with a complete review of operations within the cleanroom to ensure those facilities, operations, and practices are also satisfactory (12,13,14).

Risk Assessment Tools

A risk assessment procedure is required to determine locations for environmental monitoring. Such risk-based approaches are recommended in ISO 14698 and regulatory authorities are increasingly asking drug manufacturers about this subject. Risk-based approaches include Failure Mode and Effects Analysis (FMEA), Fault Tree Analysis (FTA), and Hazard Analysis and Critical Control Points (HACCP), Quantitative Microbiological Risk Assessment (QMRA). (10,11).

Objective of Study

1.The scope of this study, is fixing the sampling spot based on risk assessment for performing environmental monitoring.

2.To correlate the result of Finger dab test and non-viable count report with the sanitization of area and cleanliness of Personnel working in the area.

MATERIAL AND METHODOLOGY

The research was conducted in Quest Pharmaceuticals Pvt., Ltd. The company has been manufacturing non sterile dosages forms (Tablet, Capsules, Semisolids and Soft gel capsules) and distributing its products throughout Nepal.

The research was designed on the basis of statistical sampling model as ISO 14644-1 for airborne particles quantification in cleanroom (Class D) and data was taken from third party report, Qual Tech Services, Total Aerobic Microbial Count based on risk based approach and Finger dab test to understand the cleanliness standard of personnel working in the areas. Clean rooms were divided into five groups as Dispensing Room-I, Granulation Room-I, Compression room-IV, Tablet Inspection room and Blister Packing room based on different Production activities done in the plant and further the individual rooms were divided in to five different sample spot as

a. Near machine where production activity is done

b. Area where the man movement is maximum

c. Difficult to clean area

d. Near Return Air Loop

e. Near Drainage area

 based on risk of contamination of products during activities to find the Hot spot areas for higher microbial load.

Study Module for Total Aerobic Microbial Count(TAMC)

Study Period: 22/06/2022- 24/06/2022 (3 days)

Media: Soyabean Casein Digest Agar and Sabouraud Dextrose Agar

Method: Settle Plate Method (90 mm Petriplates)

Limit: Not more than 100 cfu/plate (4 hours Exposure) 25 plates of Soyabean Casein Digest Agar and 25 plates of Sabouraud Dextrose Agar was exposed for 4 hours in all sampling points. The study was conducted for three successive days. Sterile Culture media plates were exposed on petriplates stand on respective sampling sites in each room for four hours. After completion of exposure time, the petriplates were aseptically transported to Microbiology laboratory. Soyabean Casein Digest Agar plates were incubated in incubator for 72 hours and Sabouraud Dextrose Agar petriplates were incubated in BOD Incubator for 5-7 days. After the completion of incubation period, colony on Petriplates were counted using Colony Counter and result were interpreted.

Finger Dab Test

Finger Dab test was performed in the Dispensing Room-I, Granulation Room-I, Compression room-IV, Tablet Inspection room and Blister Packing room from the personnel working in the respective areas. In-house Limit of Finger Dab test was set to 100 cfu as the production area was operating in class D area and non-sterile solid dosages was formulated in the area. Personnel working in areas were selected randomly and each of them was evaluated by finger DAB test. All the fingers including thumb of personnel’s gloves were gently imprinted and impression of all these workers were obtained on labeled Perti plates containing Soyabean casein digest agar. All the plates were incubated for at 35°C for 72 hours and results were recorded.

Non-Viable Count

Report of Third party validation is taken and is performed by Qual Tech Services as approved vendor for Clean room validation in the plant.

RESULT AND DISCUSSION

1. Result of Viable Microbial Count

1.Dispensing Room-I


S. No

Sampling Location

TAMC CFU/Plate

TYMC CFU/Plate

Result

 

Day-I

Day-II

Day-III

Day-I

Day-II

Day-III

 

1

Near Machine

84

92

84

21

28

28

Complies

2

Area with maximum man movement

94

75

82

30

31

38

Complies

3

Difficult to clean area

84

81

78

24

26

32

Complies

4

Near return air loop

96

93

90

41

47

42

Complies

5

Near Drainage area

92

77

90

16

26

32

Complies


2.Granulation Room-I

 

S. No

Sampling Location

TAMC CFU/Plate

TYMC CFU/Plate

Result

 

Day-I

Day-II

Day-III

Day-I

Day-II

Day-III

 

1

Near Machine

65

67

70

32

36

36

Complies

2

Area with maximum man movement

85

89

92

33

39

41

Complies

3

Difficult to clean area

80

76

83

25

31

32

Complies

4

Near return air loop

90

94

98

45

46

48

Complies

5

Near Drainage area

75

65

70

32

25

34

Complies


3.Compression Room-IV

 

S. No

Sampling Location

TAMC

CFU/Plate

TYMC

CFU/Plate

Result

 

Day-I

Day-II

Day-III

Day-I

Day-II

Day-I

Day-II

1

Near Machine

62

71

66

25

34

36

Complies

2

Area with maximum man movement

88

78

80

28

33

36

Complies

3

Difficult to clean area

65

67

78

26

37

32

Complies

4

Near return air loop

97

86

92

46

42

44

Complies

5

Near Drainage area

80

78

84

37

40

34

Complies


4.Tablet Inspection Room

 

S. No

Sampling Location

TAMC

CFU/Plate

TYMC

CFU/Plate

Result

 

Day-I

Day-II

Day-III

Day-I

Day-II

Day-III

 

1

Near Machine

17

12

22

8

10

13

Complies

2

Area with maximum man movement

23

26

25

12

14

16

Complies

3

Difficult to clean area

31

33

18

17

17

23

Complies

4

Near return air loop

50

37

47

13

18

28

Complies

5

Near Drainage area

21

37

22

7

10

13

Complies


5. Blister Packing Room-II

 

S. No

Sampling Location

TAMC

CFU/Plate

TYMC

CFU/Plate

Result

 

Day-I

Day-II

Day-III

Day-I

Day-II

Day-III

 

1

Near Machine

90

96

87

36

37

42

Complies

2

Area with maximum man movement

96

95

88

40

42

40

Complies

3

Difficult to clean area

95

93

90

34

40

32

Complies

4

Near return air loop

99

100

97

42

45

43

Complies

5

Near Drainage area

90

88

95

38

40

40

Complies


After reviewing the results obtained for different locations of five different rooms, it can be concluded that the results are under to the defined limits. The worst case location is “Near Return Air Loop”. The TAMC and TYMC, was observed high at sampling Location “Near Return Air Loop” in comparison to the other sampling Locations for three consecutive days.

2.Result of Finger Dab Test

 

S.No.

Sample Code No.

Sampling Location

TAMC(CFU/Plate)

TAMC(CFU/Plate)

Result

Right Hand

Left Hand

1

49

Dispensing Room-I

30

42

Complies

2

99

Dispensing Room-I

67

69

Complies

3

124

Granulation Room-I.

34

28

Complies

4

91

Granulation Room-I.

40

52

Complies

5

72

Compression Room-IV

48

58

Complies

6

58

Compression Room-IV

49

48

Complies

7

42

Tablet Inspection room

66

57

Complies

8

111

Tablet Inspection room

78

65

Complies

9

56

Blister Packing Room-II

37

68

Complies

10

118

Blister Packing Room-II

67

83

Complies


In House Limit: Not more than 100 cfu/5 finger

Altogether tested 10 samples in 5 different rooms in the working areas, the cleanliness status of personnel was found satisfactory according to In-house limit. The result of right hand (five finger) and Left hand (five finger) was in the specified in house limit for finger dab test.

Result of Non-Viable Count (Rest Condition).

 

S. No.

Room /Sampling area

0.5 Micron

5.0 micron

Result

1

Dispensing Room-I

315500

6070

Complies

2

Granulation Room-I.

430496

3082

Complies

3

Compression Room-IV

303797

6700

Complies

4

Tablet Inspection room

472376

3068

Complies

5

Blister Packing Room-II

337048

2444

Complies


Limit as per ISO-14644-1:2015 in mtr3 for Particle count (7)

S. No.

ISO Class

0.5 micron

5.0 micron

1

ISO-08

35,20,000

29,300

 

 

 


The data from third party (Qual Tech Services) for Non-viable count under rest condition in the 5 different rooms in the working areas were satisfactory and within limit for ISO-8 class.

CONCLUSION

For determining the worst location, the obtained data of viable microbial count suggests that the worst case location is “Near Return Air Loop”. This location can be selected as “Hot Spot” for regular environmental monitoring of rooms. This study and results can be extensively used as a basis for marking the “Near Return Air Loop” of clean rooms as a “Hot Spot” use the area as regular Environment monitoring of clean rooms. As far as the result of Non-viable count and finger dab test are concerned, they are at satisfactory level for class

ISO-8.

REFERENCES

  1. Good manufacturing practices for sterile pharmaceutical preparations in: WHO Expert C12ommittee on Specifications for Pharmaceutical Preparations. Forty-fourth Report, Geneva, World Health Organization, 2012.
  2. ISO 11737-1. Sterilization of medical devices-Microbiological methods-determination of a population of microorganisms on products, 2007.
  3. M. Ratajczak, D. Kubicka, P. Kami?ska, Sawicka and D?ugaszewska., Saudi. Pharma. J. 2015, 23(3), 303-307.
  4. V. Parag, K. Vivekanand Bhatia., J. Pharma. Res. Clinic. Practice. 2014, 4(3), 22-32.
  5. USP. Microbiological control and monitoring environments used for the manufacture of healthcare products, Chapter 1116, Pharm Forum., 2007, 33(3).
  6. USP NF (1116) Microbiological Control and Monitoring of Aseptic Processing Environments.
  7. ISO 14644-1. Cleanrooms and associated controlled environments, classification of air cleanliness, 2015.
  8. ISO 14644-2 Cleanrooms and Associated Controlled Environments – Specifications for Testing and Monitoring to prove continued compliance with ISO 14644-1.
  9. ISO 14698-1 Cleanrooms and Associated Controlled Environments Bio contamination Control – Part 1: General Principles.
  10. W. Whyte. and T. Eaton. ‘Microbiological Contamination Models for Use in Risk Assessment during Pharmaceutical Production,’ European Journal of Parenteral and Pharmaceutical Sciences, 2004 Vol. 9, No.1, pp: 11-15.
  11. W. Whyte. and T. Eaton. ‘Microbiological Risk Assessment in Pharmaceutical Cleanrooms,’ European Journal of Parenteral and Pharmaceutical Sciences, 2004, Vol. 9, No.1, pp: 16-23.
  12. T. Sandle. ‘The Use of a Risk Assessment in the Pharmaceutical Industry – the Application of FMEA to a Sterility Testing Isolator: a Case Study,’ European Journal of Parenteral and Pharmaceutical Sciences, 2003 8(2): 43-49. 
  13. T. Sandle ‘Selection and Use of Cleaning and Disinfection Agents in Pharmaceutical Manufacturing’ in Hodges, N and Hanlon, G. (2003): ‘Industrial Pharmaceutical Microbiology Standards and Controls,’ Euromed Communications, England.
  14. T. Sandle. ‘General Considerations for the Risk Assessment of Isolators Used for Aseptic Processes,’ Pharmaceutical Manufacturing and Packaging Sourcer, Samedan Ltd, Winter 2004, pp: 43-47.
  15. PDA Technical Report No. 13 (revised): 'Fundamentals of an Environmental Monitoring Programme,' September/October 2001..

Reference

  1. Good manufacturing practices for sterile pharmaceutical preparations in: WHO Expert C12ommittee on Specifications for Pharmaceutical Preparations. Forty-fourth Report, Geneva, World Health Organization, 2012.
  2. ISO 11737-1. Sterilization of medical devices-Microbiological methods-determination of a population of microorganisms on products, 2007.
  3. M. Ratajczak, D. Kubicka, P. Kami?ska, Sawicka and D?ugaszewska., Saudi. Pharma. J. 2015, 23(3), 303-307.
  4. V. Parag, K. Vivekanand Bhatia., J. Pharma. Res. Clinic. Practice. 2014, 4(3), 22-32.
  5. USP. Microbiological control and monitoring environments used for the manufacture of healthcare products, Chapter 1116, Pharm Forum., 2007, 33(3).
  6. USP NF (1116) Microbiological Control and Monitoring of Aseptic Processing Environments.
  7. ISO 14644-1. Cleanrooms and associated controlled environments, classification of air cleanliness, 2015.
  8. ISO 14644-2 Cleanrooms and Associated Controlled Environments – Specifications for Testing and Monitoring to prove continued compliance with ISO 14644-1.
  9. ISO 14698-1 Cleanrooms and Associated Controlled Environments Bio contamination Control – Part 1: General Principles.
  10. W. Whyte. and T. Eaton. ‘Microbiological Contamination Models for Use in Risk Assessment during Pharmaceutical Production,’ European Journal of Parenteral and Pharmaceutical Sciences, 2004 Vol. 9, No.1, pp: 11-15.
  11. W. Whyte. and T. Eaton. ‘Microbiological Risk Assessment in Pharmaceutical Cleanrooms,’ European Journal of Parenteral and Pharmaceutical Sciences, 2004, Vol. 9, No.1, pp: 16-23.
  12. T. Sandle. ‘The Use of a Risk Assessment in the Pharmaceutical Industry – the Application of FMEA to a Sterility Testing Isolator: a Case Study,’ European Journal of Parenteral and Pharmaceutical Sciences, 2003 8(2): 43-49. 
  13. T. Sandle ‘Selection and Use of Cleaning and Disinfection Agents in Pharmaceutical Manufacturing’ in Hodges, N and Hanlon, G. (2003): ‘Industrial Pharmaceutical Microbiology Standards and Controls,’ Euromed Communications, England.
  14. T. Sandle. ‘General Considerations for the Risk Assessment of Isolators Used for Aseptic Processes,’ Pharmaceutical Manufacturing and Packaging Sourcer, Samedan Ltd, Winter 2004, pp: 43-47.
  15. PDA Technical Report No. 13 (revised): 'Fundamentals of an Environmental Monitoring Programme,' September/October 2001..

Photo
Shrawan Kr. Singh
Corresponding author

Quest Pharmaceuticals, Nepal

Photo
Dr. Kamlesh Dutta
Co-author

Quest Pharmaceuticals, Nepal

Photo
Ravi Chaudhary
Co-author

Quest Pharmaceuticals, Nepal

Shrawan Kr. Singh*, Dr. Kamlesh Dutta, Ravi Chaudhary, Risk Based Study of Sample Spot Fixing for Conducting Environmental Monitoring Test in Classified Areas of Pharmaceutical Industry, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 2, 146-152. https://doi.org/10.5281/zenodo.14793799

More related articles
Advances in Bacterial Classification: From Phenoty...
Dr. Malavika Bhattacharya, Ananya Das, Rojina Khatun, Sudeshna Se...
Cardiovascular And Metabolic Abnormalities Induced...
Benson P Wilson , Sona sojan, Athul Krishna SA , Assish p Antony ...
A Study To Identify The Prevelance Of Covid 19 Vac...
Vilas Pai, SATISH S, RAMAKRISHNA SHABARAYA A, ...
A Comprehensive Scientific Overview of Camellia sinensis (Green Tea): Historical...
Vaibhav Madane, Akash Narbat, Priyanka Waghmode, Namdeo Shinde, Sanil Khandekar, Bapu Khandekar, ...
A Detail Review on Phytochemistry and Pharmacology of Solanum Viarum...
Indu, Dr. Dev Prakash Dahiya, Anchal Sankhyan, Anjali Thakur, Anjali Sharma, Shelly, ...
Aromatherapy And Beyond: The Pharmacological Profile of Chamomile- A Review...
Vaishnavi Khot , Amruta Patil , Iftesam Momin, Aniket Thanekar , Dr. Dhanraj Jadge, ...
Related Articles
Advanced Analytical Strategies for Antibiotic Quantification: A Comparative Stud...
Samadhan Anarse , Janhvi Bora, Tejal Bhalshankar, Vaisnavi Gadilkar, Shubham Gaikawad, Dr. Shoheb Sh...
Herbal Soaps: A Natural Alternative for Skin Care...
Akash Gaikwad , Aniket Gudur, Rini Punathil, Sanket Dharashivkar, ...
Recent Biomarker in Alzheimer’s Disease: A Systemic Review...
Sabitri Pradhan , Rintu Saikia , Pranita Sunar, ...
Synthesis, Characterization and In-Silico Studies of Novel Thiazolidine Derivati...
Raja Waleed Sajjad, Hammad Nasir, Saba Manzoor, Muhammad Mueen, Syeda Fatima Ashoor, Raja Ahmed, Ash...
Advances in Bacterial Classification: From Phenotypic Traits to Genomic Signatur...
Dr. Malavika Bhattacharya, Ananya Das, Rojina Khatun, Sudeshna Sengupta, ...
More related articles
Advances in Bacterial Classification: From Phenotypic Traits to Genomic Signatur...
Dr. Malavika Bhattacharya, Ananya Das, Rojina Khatun, Sudeshna Sengupta, ...
Cardiovascular And Metabolic Abnormalities Induced By Antipsychotic Drug Therapy...
Benson P Wilson , Sona sojan, Athul Krishna SA , Assish p Antony , Happy Thomas , ...
Advances in Bacterial Classification: From Phenotypic Traits to Genomic Signatur...
Dr. Malavika Bhattacharya, Ananya Das, Rojina Khatun, Sudeshna Sengupta, ...
Cardiovascular And Metabolic Abnormalities Induced By Antipsychotic Drug Therapy...
Benson P Wilson , Sona sojan, Athul Krishna SA , Assish p Antony , Happy Thomas , ...